Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation

Drug Discov Today. 2023 Aug;28(8):103671. doi: 10.1016/j.drudis.2023.103671. Epub 2023 Jun 16.

Abstract

Rheumatoid arthritis (RA) is an inflammatory, autoimmune and connective-tissue arthropathy. The methotrexate (MTX) and aceclofenac (ACL) combination drug regimen is known to regulate the immunological pathways. Also, RA-elicited inflammation is decreased by the combination drug treatment. ACL and MTX combination treatment has been shown to regulate the signaling pathway controlled by NF-κB and FOXO1. The present manuscript reviews the importance of the combination drug regimen to treat and/or manage RA. The combination drug regimen could affect the Th1/Th17 axis to switch the balance toward the immunoregulatory (Th1) phenotype for establishing immune homeostasis. In conclusion, we propose the study of the immunological signaling pathways in experimental humanized RA mice.

Keywords: Methotrexate; aceclofenac; combination drug regimen; humanized mice; inflammation; nanoparticle; rheumatoid arthritis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antirheumatic Agents* / pharmacology
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Experimental* / drug therapy
  • Arthritis, Experimental* / metabolism
  • Arthritis, Rheumatoid* / drug therapy
  • Drug Therapy, Combination
  • Inflammation / drug therapy
  • Methotrexate / pharmacology
  • Methotrexate / therapeutic use
  • Mice

Substances

  • Methotrexate
  • Antirheumatic Agents
  • aceclofenac